Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...

Pi moderators publicly rejected the "Global Consensus Value" myth as harmful misinformation, with the launch preparation of Map of Pi 2.0. Summary is AI generated, newsroom reviewed. Pi moderators ...

Pi Network whale accumulation boosts PI coin despite Bitcoin and Ethereum losses. Map of Pi 2.0 to enable real-world transactions with 140,000+ merchants. Moderators debunk GCV, emphasising utility ...

Pi Coin nears breakout with rising inflows as Pi Network debunks GCV claims and prepares for the Map of Pi 2.0 launch. Pi Coin is nearing a critical breakout point after consolidating within a ...

Some of the offered footprints of the Raspberry Pi Pico; additional more specific footprints also included. Some of the offered schematic symbols of the Raspberry Pi Pico; many pins provide alternate ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...